Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

ABSTRACT: The purpose of this study is to compare transcriptional profiles of non-small-cell lung cancer between responder patients and non-responder patients during anti-PD-1 treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE126043 | GEO | 2020/09/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

Project description:The purpose of this study is to compare transcriptional profiles of non-small-cell lung cancer between responder patients and non-responder patients during anti-PD-1 treatment.

2020-02-03 | GSE126044 | GEO

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer.

Project description: Not available

| S-EPMC8080767 | biostudies-literature

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-02-03 | GSE126045 | GEO

Proteomics of the Gastric cancer Response to anti-PD1 therapy

Project description:To validate the correlation between Th1/Th2 ratio and immunotherapeutic effectiveness, we collected a group of GC patients treated with anti-PD1 therapy, including 7 responder cases (PR) and 7 non-responder cases (SD/PD). The formalin-fixed paraffin-embedded (FFPE) tumor tissue sections derived from 14 therapy-naïve GC patients were collected.

2022-11-17 | PXD038188 |

Proteomic profiling to predict therapeutic response to anti-PD1 therapy in advanced melanoma

Project description:Purpose Antibody-blockade of PD-1 shows durable responses, but so far, few biomarkers accurately predict if patients with metastatic melanoma will respond. Experimental design We analyzed baseline serum samples (n=56) and tumor cell cultures (n=8), from melanoma patients treated with anti-PD1 therapy. Two approaches concentrating low abundant proteins in serum and two different mass spectrometry (MS) methods were applied: depletion of high abundant proteins with shotgun-MS, and N-glycosite enrichment combined with SWATH-MS. Tumor cell cultures were processed as whole cell lysates with subsequent shotgun-MS. Results Focusing on the non-responder proteome, we identified pathways such as inflammatory processes, cell adhesion and migration, scavenger receptor activity, RAGE receptor binding, platelet aggregation, neutrophil degranulation and integrin signaling to be upregulated. Analyzing the tumor cell proteome revealed a distinctive immunophenotype with CD antigens highly overexpressed in non-responders. Validation of a subset of these markers, performed by immunofluorescence staining of a tissue microarray, revealed a higher mean of positive cells in the tumor microenvironment of non-responders. Validation of serum proteome markers on a second baseline cohort by using a timsTOF for ion mobility MS, revealed significant differences between responder and non-responder for the proteins ORM2, SERPINA1, EFEMP1, and VASN. TCGA survival analysis demonstrated prognostic significance for multiple proteins of our signature correlating with lower overall survival in melanoma patients. Based on this study, we suggest a protein-panel for responsiveness to PD-1 blockade consisting of 14 serum and 33 tumor cell markers that will be the basis for further research.

2023-08-18 | PXD027525 | Pride

Survey of differentially methylated promoters in prostate cancer cell lines.

Project description: Not available

| S-EPMC1501885 | biostudies-literature

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

Project description:Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

| PRJNA520852 | ENA

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

Project description:Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

| PRJNA520848 | ENA

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

Project description:Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

| PRJNA520851 | ENA

Regeneration and developmental enhancers are differentially compatible with minimal promoters.

Project description: Not available

| S-EPMC10211259 | biostudies-literature